LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 65

Search options

  1. Article ; Online: Third-Generation Solid Dispersion Through Lyophilization Enhanced Oral Bioavailability of Resveratrol.

    Almeida, Hugo / Ferreira, Bárbara / Fernandes-Lopes, Carlos / Araújo, Francisca / Bonifácio, Maria João / Vasconcelos, Teófilo / Sarmento, Bruno

    ACS pharmacology & translational science

    2024  Volume 7, Issue 3, Page(s) 888–898

    Abstract: Resveratrol (RES) is a biopharmaceutical classification system (BCS) class II compound with low solubility and high permeability. Several strategies have been explored to overcome the low bioavailability of RES, making the formation of solid dispersions ( ...

    Abstract Resveratrol (RES) is a biopharmaceutical classification system (BCS) class II compound with low solubility and high permeability. Several strategies have been explored to overcome the low bioavailability of RES, making the formation of solid dispersions (SDs) one of the most promising. This study aimed at the development of a RES third-generation SD prepared by lyophilization as a strategy to improve RES solubility, dissolution, and oral bioavailability. Eudragit E PO was selected as the hydrophilic carrier in a 1:2 (RES:carrier) ratio, and Gelucire 44/14 as the surfactant, at 16% (w/w) of RES. Differential scanning calorimetry (DSC), scanning electron microscopy (SEM), Fourier-transform infrared spectroscopy (FTIR), polarized light microscopy (PLM), X-ray powder diffraction (XRPD), and particle size distribution (Morphologi 4 Malvern) were used for solid-state characterization and to confirm the conversion of RES to the amorphous state in the SD. Third-generation SD presented an 8-, 12-, and 8-fold increase of RES solubilized compared to pure RES at pH 1.2, 4.5, and 6.8, respectively, and a 10-fold increase compared to the physical mixture (PM), at pH 6.8, after 24 h. In the gastric environment, the dissolution rate of third-generation SD and PM was similar, and 2-fold higher than pure RES after 30 min, while at pH 6.8, third-generation SD presented approximately a 5-fold increase in comparison to pure RES and PM. Third-generation SD presented higher in vitro intestinal permeability compared to its PM and second-generation SD (without Gelucire 44/14). A 2.4 and 1.7-fold increase of RES permeated, respectively in Caco-2 and Caco-2/HT2-MTX models, was obtained with third-generation SD compared to PM, after 3 h. Third-generation SD allowed a 3-fold increase of RES bioavailability compared to second-generation SD, after oral administration of 200 mg/kg of RES to Wistar rats. Enhanced RES oral bioavailability was obtained not only by solubility and dissolution improvement, but also by the interference of Gelucire 44/14, with RES metabolism, and inhibition of P-gp-mediated efflux. The presence of excipients like Gelucire 44/14 in the SD allows for greater bioavailability of orally administered RES, making it easier to obtain some of the physiological benefits demonstrated by this molecule.
    Language English
    Publishing date 2024-02-14
    Publishing country United States
    Document type Journal Article
    ISSN 2575-9108
    ISSN (online) 2575-9108
    DOI 10.1021/acsptsci.4c00029
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys.

    Bonifácio, Maria João / Sousa, Filipa / Soares-da-Silva, Patrício

    European journal of pharmacology

    2020  Volume 892, Page(s) 173742

    Abstract: Opicapone is a third generation nitrocatechol catechol-O-methyltransferase inhibitor that has received regional market approval for use as adjunctive therapy to levodopa in Parkinson's disease patients with motor fluctuations. This study evaluated the ... ...

    Abstract Opicapone is a third generation nitrocatechol catechol-O-methyltransferase inhibitor that has received regional market approval for use as adjunctive therapy to levodopa in Parkinson's disease patients with motor fluctuations. This study evaluated the effects of opicapone as adjunct to levodopa in reversing a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced Parkinson's-like syndrome in cynomolgus monkeys in during opicapone preclinical development program. A Parkinson's-like syndrome was induced in cynomolgus monkeys by daily administrations of MPTP. Evaluation of the animals included scoring with the Primate Parkinsonism Motor Rating Scale (PPMRS) and assessment of locomotor activity. MPTP produced a stable Parkinson's-like behavioural syndrome as evidenced by tremor, postural changes, rigidity, impaired movements and balance, (PPMRS scores of 10-15) and decreased locomotor activity (13% of pre-MPTP values). Opicapone treatment alone, for 14 days, did not change Parkinson's-like symptoms nor decreased subject's locomotor behaviour. Ascending combinations of levodopa/benserazide dose-dependently decreased PPMRS and improved locomotor behaviour reaching statistical significance for levodopa/benserazide doses of 18/4.5 mg/kg and those effects were enhanced in opicapone treated subjects. Opicapone treated subjects as compared vehicle-treated, had markedly reduced erythrocyte catechol-O-methyltransferase activity, significantly increased plasma levodopa levels (1.8-fold higher AUC) with no statistically significant changes in C
    MeSH term(s) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine ; Animals ; Antiparkinson Agents/pharmacology ; Behavior, Animal/drug effects ; Catechol O-Methyltransferase Inhibitors/pharmacology ; Disease Models, Animal ; Drug Therapy, Combination ; Erythrocytes/drug effects ; Erythrocytes/enzymology ; Female ; Levodopa/pharmacology ; Locomotion/drug effects ; Macaca fascicularis ; Oxadiazoles/pharmacology ; Parkinsonian Disorders/chemically induced ; Parkinsonian Disorders/drug therapy ; Parkinsonian Disorders/enzymology ; Parkinsonian Disorders/physiopathology ; Time Factors
    Chemical Substances Antiparkinson Agents ; Catechol O-Methyltransferase Inhibitors ; Oxadiazoles ; Levodopa (46627O600J) ; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (9P21XSP91P) ; opicapone (Y5929UIJ5N)
    Language English
    Publishing date 2020-11-18
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 80121-5
    ISSN 1879-0712 ; 0014-2999
    ISSN (online) 1879-0712
    ISSN 0014-2999
    DOI 10.1016/j.ejphar.2020.173742
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Voltage-clamp evidence of GABA

    Fernandes, Hélder / Batalha, Vânia / Braksator, Ellen / Hebeisen, Simon / Bonifácio, Maria João / Vieira-Coelho, Maria Augusta / Soares-da-Silva, Patrício

    Pharmacological reports : PR

    2022  Volume 74, Issue 5, Page(s) 956–968

    Abstract: Background: Anxiolytic benzodiazepines, due to their clinical effectiveness, are one of the most prescribed drugs worldwide, despite being associated with sedative effects and impaired psychomotor and cognitive performance. Not every GABA: Methods: ... ...

    Abstract Background: Anxiolytic benzodiazepines, due to their clinical effectiveness, are one of the most prescribed drugs worldwide, despite being associated with sedative effects and impaired psychomotor and cognitive performance. Not every GABA
    Methods: The present study pharmacodynamically evaluated chlornordiazepam, the main active metabolite of mexazolam, upon GABA
    Results: As shown by whole-cell patch-clamp data, chlornordiazepam potentiated GABA-evoked current amplitude in α2 and α3 containing receptors without changing the current amplitude in α1 containing receptors. However, current decay time increased, particularly in GABA
    Conclusions: This novel evidence demonstrates that mexazolam (through its main metabolite chlornordiazepam) has a "pharmacodynamic fingerprint" that correlates better with an anxiolytic profile and fewer sedative effects, when compared to alprazolam, bromazepam and zolpidem, explaining clinical trial outcomes with these drugs. This also highlights the relevance of the pharmacological selectivity over GABA
    MeSH term(s) Receptors, GABA-A/metabolism ; Zolpidem ; Alprazolam/pharmacology ; Anti-Anxiety Agents/pharmacology ; Bromazepam/pharmacology ; Benzodiazepines/pharmacology ; Hypnotics and Sedatives/pharmacology ; gamma-Aminobutyric Acid
    Chemical Substances mexazolam (S5969B6237) ; Receptors, GABA-A ; Zolpidem (7K383OQI23) ; Alprazolam (YU55MQ3IZY) ; Anti-Anxiety Agents ; Bromazepam (X015L14V0O) ; Benzodiazepines (12794-10-4) ; Hypnotics and Sedatives ; gamma-Aminobutyric Acid (56-12-2)
    Language English
    Publishing date 2022-09-12
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2186248-5
    ISSN 2299-5684 ; 1734-1140
    ISSN (online) 2299-5684
    ISSN 1734-1140
    DOI 10.1007/s43440-022-00411-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Absorption, metabolism and excretion of opicapone in human healthy volunteers.

    Loureiro, Ana I / Rocha, Francisco / Santos, Ana T / Singh, Nand / Bonifácio, Maria João / Pinto, Rui / Kiss, Laszlo E / Soares-da-Silva, Patrício

    British journal of clinical pharmacology

    2022  Volume 88, Issue 10, Page(s) 4540–4551

    Abstract: Aims: The absorption, metabolism and excretion of opicapone (2,5-dichloro-3-(5-[3,4-dihydroxy-5-nitrophenyl]-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide), a selective catechol-O-methyltransferase inhibitor, were investigated.: Methods: Plasma, ...

    Abstract Aims: The absorption, metabolism and excretion of opicapone (2,5-dichloro-3-(5-[3,4-dihydroxy-5-nitrophenyl]-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide), a selective catechol-O-methyltransferase inhibitor, were investigated.
    Methods: Plasma, urine and faeces were collected from healthy male subjects following a single oral dose of 100 mg [
    Results: The recovery of total administered radioactivity averaged >90% after 144 hours. Faeces were the major route of elimination, representing 70% of the administered dose; 5% and 20% were excreted in urine and expired air, respectively. The C
    Conclusion: [
    MeSH term(s) Administration, Oral ; Catechol O-Methyltransferase Inhibitors/pharmacokinetics ; Feces ; Healthy Volunteers ; Humans ; Male ; Oxadiazoles/pharmacokinetics
    Chemical Substances Catechol O-Methyltransferase Inhibitors ; Oxadiazoles ; opicapone (Y5929UIJ5N)
    Language English
    Publishing date 2022-05-20
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 188974-6
    ISSN 1365-2125 ; 0306-5251 ; 0264-3774
    ISSN (online) 1365-2125
    ISSN 0306-5251 ; 0264-3774
    DOI 10.1111/bcp.15383
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Metabolism and disposition of opicapone in the rat and metabolic enzymes phenotyping.

    Loureiro, Ana I / Fernandes-Lopes, Carlos / Bonifácio, Maria João / Sousa, Filipa / Kiss, László E / Soares-da-Silva, Patricio

    Pharmacology research & perspectives

    2021  Volume 10, Issue 1, Page(s) e00891

    Abstract: Opicapone (2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide) is a selective catechol-O-methyltransferase inhibitor that has been granted marketing authorization in Europe, Japan, and United States. The ... ...

    Abstract Opicapone (2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide) is a selective catechol-O-methyltransferase inhibitor that has been granted marketing authorization in Europe, Japan, and United States. The present work describes the metabolism and disposition of opicapone in the rat obtained in support to its development and regulatory filling. Plasma levels and elimination of total radioactivity were determined after oral and intravenous administration of [
    MeSH term(s) Administration, Intravenous ; Administration, Oral ; Animals ; Arylsulfotransferase/metabolism ; Catechol O-Methyltransferase Inhibitors/administration & dosage ; Catechol O-Methyltransferase Inhibitors/pharmacokinetics ; Glucuronosyltransferase/metabolism ; Male ; Oxadiazoles/administration & dosage ; Oxadiazoles/pharmacokinetics ; Phenotype ; Rats ; Rats, Wistar ; Tissue Distribution
    Chemical Substances Catechol O-Methyltransferase Inhibitors ; Oxadiazoles ; Glucuronosyltransferase (EC 2.4.1.17) ; Arylsulfotransferase (EC 2.8.2.1) ; Sult1a1 protein, rat (EC 2.8.2.1) ; opicapone (Y5929UIJ5N)
    Language English
    Publishing date 2021-12-22
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2740389-0
    ISSN 2052-1707 ; 2052-1707
    ISSN (online) 2052-1707
    ISSN 2052-1707
    DOI 10.1002/prp2.891
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Balancing trade-offs: Enhanced carbon assimilation and productivity with reduced nutritional value in a well-watered C

    Habermann, Eduardo / Dias de Oliveira, Eduardo Augusto / Bianconi, Matheus Enrique / Contin, Daniele Ribeiro / Lemos, Maria Teresa Oliverio / Costa, João Vitor Campos Pinho / Oliveira, Kamilla Silva / Riul, Beatriz Neroni / Bonifácio-Anacleto, Fernando / Viciedo, Dilier Olivera / Approbato, Andressa Uehara / Alzate-Marin, Ana Lilia / Prado, Renato de Mello / Costa, Katia Aparecida de Pinho / Martinez, Carlos Alberto

    Plant physiology and biochemistry : PPB

    2024  Volume 207, Page(s) 108408

    Abstract: The concentration of atmospheric ... ...

    Abstract The concentration of atmospheric CO
    MeSH term(s) Animals ; Carbon Dioxide/metabolism ; Ecosystem ; Water/metabolism ; Atmosphere ; Photosynthesis ; Poaceae/metabolism ; Plant Leaves/metabolism ; Nutritive Value
    Chemical Substances Carbon Dioxide (142M471B3J) ; Water (059QF0KO0R)
    Language English
    Publishing date 2024-02-15
    Publishing country France
    Document type Journal Article
    ZDB-ID 742978-2
    ISSN 1873-2690 ; 0981-9428
    ISSN (online) 1873-2690
    ISSN 0981-9428
    DOI 10.1016/j.plaphy.2024.108408
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Conference proceedings: DOENÇA DE CROHN METASTÁTICA PARA AS REGIÕES PENIANA E INGUINAL: RELATO DE CASO

    Avelar, João Victor de Miranda / Vicente, Marina Tambasco Freire / Bonifácio, Marcelo Filipe Andrade / Lacerda, Isadora Paiva / Evangelista, Rogério Khalil Akkari / Raimundo, Roberta Oliveira / Chebli, Júlio Maria Fonseca / Chebli, Liliana Andrade

    Journal of Coloproctology

    2023  Volume 43, Issue S 01

    Event/congress 71° Congresso Brasileiro de Coloproctologia, Belo Horizonte, MG, 2023-09-05
    Language English
    Publishing date 2023-12-01
    Publisher Thieme Revinter Publicações Ltda.
    Publishing place Stuttgart ; New York
    Document type Article ; Conference proceedings
    ZDB-ID 2664477-0
    ISSN 2317-6423 ; 2237-9363 ; 2317-6423
    ISSN (online) 2317-6423
    ISSN 2237-9363 ; 2317-6423
    DOI 10.1055/s-0044-1781050
    Database Thieme publisher's database

    More links

    Kategorien

  8. Article: Carbamazepine aggravates absence seizures in two dedicated mouse models.

    Pires, Nuno Marques / Bonifácio, Maria João / Soares-da-Silva, Patrício

    Pharmacological reports : PR

    2015  Volume 67, Issue 5, Page(s) 986–995

    Abstract: Background: The aim of this study was to evaluate the effect of carbamazepine (CBZ) upon chemically induced absence seizures and in a genetic absence seizures model in the mouse.: Methods: The γ-butyrolactone (GBL)-induced acute absence seizures and ... ...

    Abstract Background: The aim of this study was to evaluate the effect of carbamazepine (CBZ) upon chemically induced absence seizures and in a genetic absence seizures model in the mouse.
    Methods: The γ-butyrolactone (GBL)-induced acute absence seizures and the stargazer spontaneous absence seizures mice models were used to characterize the aggravation of absence seizures induced by oral CBZ treatment. The effect of CBZ upon GABA inward-currents in Ltk cells expressing human recombinant α1β2γ2, α2β2γ2, α3β2γ2 and α5β2γ2 GABAA receptors was evaluated by means of patch clamp.
    Results: GBL administration induced motor impairment in NMRI mice. High dose CBZ (25mg/kg body weight) had no effect on motor performance but exacerbated the behavioral incoordination observed for GBL. Also, coadministration of a high dose CBZ and GBL impaired spontaneous locomotion. Moreover, CBZ was investigated after oral administration to evaluate the potential to aggravate GBL-induced acute spike-and-wave discharges (SWD) in the electroencephalogram. High dose CBZ significantly aggravated SWD induced by GBL. Likewise, in the stargazer mouse model of genetic spontaneous absence seizures, CBZ significantly aggravated SWD frequency and duration. Pre-treatment with the T-type Ca(2+) channel blocker ethosuximide (200mg/kg body weight) prevented the CBZ aggravation of SWD induced by GBL and in the stargazer mouse. CBZ increased in a concentration dependent manner sub-maximal α1β2γ2 and α3β2γ2 GABA currents.
    Conclusion: CBZ aggravates absence seizures as assessed in two dedicated mouse models of absence seizures. Facilitation of sub-maximal α1β2γ2, and α3β2γ2 GABA currents by CBZ may play a role in CBZ-induced GABA-mediated aggravation of absence seizures.
    MeSH term(s) 4-Butyrolactone ; Animals ; Anticonvulsants/toxicity ; Calcium Channels, T-Type/drug effects ; Calcium Channels, T-Type/metabolism ; Carbamazepine/toxicity ; Dose-Response Relationship, Drug ; Electroencephalography ; Epilepsy, Absence/chemically induced ; Epilepsy, Absence/genetics ; Epilepsy, Absence/physiopathology ; Ethosuximide/pharmacology ; Male ; Mice ; Mice, Inbred Strains ; Motor Activity/drug effects ; Patch-Clamp Techniques ; Psychomotor Performance/drug effects ; Receptors, GABA-A/drug effects ; Receptors, GABA-A/genetics
    Chemical Substances Anticonvulsants ; Calcium Channels, T-Type ; Receptors, GABA-A ; Carbamazepine (33CM23913M) ; Ethosuximide (5SEH9X1D1D) ; 4-Butyrolactone (OL659KIY4X)
    Language English
    Publishing date 2015-03-23
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2186248-5
    ISSN 1734-1140
    ISSN 1734-1140
    DOI 10.1016/j.pharep.2015.03.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Prebiotic effects of olive pomace powders in the gut: In vitro evaluation of the inhibition of adhesion of pathogens, prebiotic and antioxidant effects

    Ribeiro, Tânia Bragança / Costa, Célia Maria / Bonifácio - Lopes, Teresa / Silva, Sara / Veiga, Mariana / Monforte, Ana Rita / Nunes, João / Vicente, António A / Pintado, Manuela

    Food hydrocolloids. 2021 Mar., v. 112

    2021  

    Abstract: Olive pomace is a biowaste rich in polyphenols and insoluble dietary fibre with high potential to develop new value chains towards a sustainable and circular bioeconomy. Regarding gut health, olive pomace phenolics and insoluble dietary fibre (after ... ...

    Abstract Olive pomace is a biowaste rich in polyphenols and insoluble dietary fibre with high potential to develop new value chains towards a sustainable and circular bioeconomy. Regarding gut health, olive pomace phenolics and insoluble dietary fibre (after possible fermentation) could act as antioxidants, antimicrobial and prebiotic agents. These potential beneficial effects on the gut were analysed for two powders from olive pomace: liquid-enriched powder (LOPP) - mostly source of phenolics - and pulp-enriched powder (POPP) - main source of insoluble dietary fibre. LOPP and POPP were subjected to an in vitro simulated gastrointestinal digestion followed by in vitro faecal fermentation. The undigested fraction retained in the colon was analysed regarding its potential antioxidant, antimicrobial and prebiotic effects. LOPP and POPP did not impact the gut microbiota diversity negatively, showing a similar ratio of Firmicutes/Bacteroidetes compared to a positive control (FOS). LOPP exhibit a positive (similar to FOS) effect on the Prevotella spp./Bacteroides spp. ratio. Both powders promoted more the production of short-chain fatty acids (mainly acetate > butyrate > propionate) than FOS and showed also significant total phenolic content and oxygen radical absorbance capacity during faecal fermentation until 48 h. Besides that, these powders showed mucin-adhesion inhibition ability against pathogens, principally POPP against Bacillus cereus (22.03 ± 2.45%) and Listeria monocytogenes (20.01 ± 1.93%). This study demonstrates that olive pomace powders have prebiotic effects on microbiota, including the stimulation of short-chain fatty acids production, potential antioxidant and antimicrobial activity which could improve the human gut health.
    Keywords Bacillus cereus ; Listeria monocytogenes ; Prevotella ; acetates ; adhesion ; antimicrobial properties ; antioxidants ; bioeconomics ; butyrates ; colon ; dietary fiber ; fermentation ; humans ; hydrocolloids ; in vitro digestion ; intestinal microorganisms ; olive pomace ; oxygen radical absorbance capacity ; polyphenols ; prebiotics ; propionic acid ; wastes
    Language English
    Dates of publication 2021-03
    Publishing place Elsevier Ltd
    Document type Article
    Note NAL-AP-2-clean
    ZDB-ID 742742-6
    ISSN 1873-7137 ; 0268-005X
    ISSN (online) 1873-7137
    ISSN 0268-005X
    DOI 10.1016/j.foodhyd.2020.106312
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  10. Article ; Online: Preclinical pharmacological evaluation of the fatty acid amide hydrolase inhibitor BIA 10-2474.

    Bonifácio, Maria-João / Sousa, Filipa / Aires, Cátia / Loureiro, Ana I / Fernandes-Lopes, Carlos / Pires, Nuno M / Palma, Pedro Nuno / Moser, Paul / Soares-da-Silva, Patrício

    British journal of pharmacology

    2020  Volume 177, Issue 9, Page(s) 2123–2142

    Abstract: Background and purpose: In 2016, one person died and four others had mild-to-severe neurological symptoms during a phase I trial of the fatty acid amide hydrolase (FAAH) inhibitor BIA 10-2474.: Experimental approach: Pharmacodynamic and ... ...

    Abstract Background and purpose: In 2016, one person died and four others had mild-to-severe neurological symptoms during a phase I trial of the fatty acid amide hydrolase (FAAH) inhibitor BIA 10-2474.
    Experimental approach: Pharmacodynamic and pharmacokinetic studies were performed with BIA 10-2474, PF-04457845 and JNJ-42165279 using mice, rats and human FAAH expressed in COS cells. Selectivity was evaluated by activity-based protein profiling (APBB) in rats. BIA 10-2474 effect in stroke-prone spontaneously hypertensive rats (SHRSP) was investigated.
    Key results: BIA 10-2474 was 10-fold less potent than PF-04457845 in inhibiting human FAAH in situ but inhibited mouse brain and liver FAAH with ED
    Conclusions and implications: BIA 10-2474 potently inhibits FAAH in vivo, similarly to PF-04457845 and interacts with a number of lipid processing enzymes, some previously identified in human cells as off-targets particularly at high levels of exposure. These interactions occurred at doses used in toxicology studies, but the implication of these off-targets in the clinical trial accident remains unclear.
    MeSH term(s) Amidohydrolases ; Animals ; Cyclic N-Oxides ; Endocannabinoids ; Enzyme Inhibitors/pharmacology ; Group VI Phospholipases A2 ; Mice ; Pyridines/pharmacology ; Rats
    Chemical Substances BIA 10-2474 ; Cyclic N-Oxides ; Endocannabinoids ; Enzyme Inhibitors ; Pyridines ; Group VI Phospholipases A2 (EC 3.1.1.4) ; Pla2g6 protein, mouse (EC 3.1.1.4) ; Amidohydrolases (EC 3.5.-) ; fatty-acid amide hydrolase (EC 3.5.1.-)
    Language English
    Publishing date 2020-02-12
    Publishing country England
    Document type Journal Article
    ZDB-ID 80081-8
    ISSN 1476-5381 ; 0007-1188
    ISSN (online) 1476-5381
    ISSN 0007-1188
    DOI 10.1111/bph.14973
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top